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Background and Objectives: Previous studies with
PhotoDynamic Therapy (PDT) in bladder and bronchi have
shown that due to scattering and reflection, the actually
delivered fluence rate on the surface in a hollow organ can
be significantly higher than expected. In this pilot study, we
investigated the differences between the primary calcu-
lated and the actual measured fluence rate during PDT of
Barrett’s Esophagus (BE) using 23 independent clinical
measurements in 15 patients.
Study Design/Materials and Methods: A KTP-dye
module laser at 630 nm was used as light source. Light
delivery was performed using a cylindrical light diffuser
inserted in the center of an inflatable transparent balloon
with a length corresponding to the length of the Barrett’s
epithelium. The total light output power of the cylindrical
diffuser was calibrated using an integrating sphere to de-
liver a primary fluence rate of 100 mW cm2. Two fiber-optic
pseudosphere isotropicdetectors wereplacedontheballoon
and were used to measure fluence rate at the surface of the
esophageal wall during PDT.
Results and Conclusions: The actual fluence rate mea-
sured was 1.5–3.9 times higher than the primary fluence
rate for 630 nm. In general, the fluence rate amplification
factor decreased with increasing redness of the tissue and
was less for shorter diffusers. Fluence rate variations in
time were observed which coincided with patients cough-
ing, movement, and esophageal spasms. These factors
combined with inter patient variability of the fluence rate
measured appears to justify the routine application of this
technique in PDT of BE. Lasers Surg. Med. 31:299–304,
2002.
 2002 Wiley-Liss, Inc.
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INTRODUCTION
Barrett’s Esophagus (BE) is a premalignant condition for
which superficial ablation might be used to reduce the risk
of malignant degeneration. The current therapy for high-
grade dysplasia is still esophagectomy but this is comprised
by a short-term morbidity of 30%. PhotoDynamic Therapy
(PDT) using 5 aminolevulinic acid (ALA) as a pro-drug for
the production of PpIX acting as photosensitiser has found
world wide interest as a potential tool for treating early
stage BE. ALA-PDT eliminates the epithelium of BE selec-
tively without damaging the entire wall of the esophagus
due to selective localisation of PpIX in the oesophageal
mucosa rather than in the underlying stroma [1–3]. PDT
for the superficial ablation of Barrett’s mucosa might be
superior to the existing therapies due to less morbidity and
mortality compared to surgery.
For PDT, the time interval between photosensitiser
administration and illumination-scheme is important.
More recently de Bruijn et al. [4] suggested a two-fold illu-
mination scheme for which a dramatic increase in tumour
volume doubling time was demonstrated. Furthermore,
light fluence rate and the fluence (also referred to as light
dose) delivered to the tissue were demonstrated to strongly
influence the severity of PDT-induced tissue damage [5]. In
previous oesophageal PDT studies [1,6–11], light dosime-
try was defined as either an estimation of the primary
fluence rate (based on the total output power of a cylindrical
diffuser divided by the area to be treated) or merely the light
output power per length of diffuser. This approach assumes
a radially emitting cylindrical diffuser and does not account
for tissue light backscattering and reflection. In previous
experiences with PDT in bladder and bronchi [12,13] we
have shown that the actually delivered fluence rate in a
hollow organ can be significantly higher than the primary
fluence rate, due to back-scattering of light from the tissue
and reflection at the tissue surface boundaries. The tissue
optical and geometrical properties are different in each
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patient, consequently the actual fluence rate will vary, and
thus may lead to either under-treatment or over-treatment.
Measuring the actual fluence rate at the oesophageal sur-
face can be expected to improve the correlation between
treatment parameters and treatment effect and may
ensure a safer illumination.
To evaluate the practical necessity of in vivo dosimetry,
we developed a balloon based light delivery system with
integrated light detection system and performed measure-
ments of the actual fluence rate during PDT in the
esophagus of 15 patients. The purpose of the dosimetry
study was: (a) to investigate the difference between the
actual and primary fluence rate, (b) to evaluate the neces-
sity of performing such measurements on a routine basis,
and (c) to investigate possible differences in fluence rate
during the second session resulting from PDT effects of the
first session of a two-fold illumination scheme. The dosi-
metric study described in this paper was performed during
a clinical pilot experiment investigating a double illumina-
tion scheme for PDT of BE. The treatment was still based on
the estimation of the primary fluence rate, hence mea-
suring the true fluence rate was of no consequence for
the treatment.
In this paper, we present the results of in situ light
dosimetry during PDT of 15 patients resulting in 23
independent measurements. From these results, we have
derived fluence rate amplification factors for all illumina-
tions. All parameters that may contribute to this factor will
be discussed.
MATERIALS AND METHODS
Light Dosimetry
A schematic representation of the inflatable balloon light
delivery/dosimetry is depicted in Figure 1.
The aim was to deliver a primary fluence rate (fprimary) of
100 mW cm2 to the esophageal surface based on a first
order approximation of the primary fluence rate in absence
of tissue.
fprimary ¼
Pout
p Dball  Ldif ð1Þ
where Dball is the balloon diameter [cm], Pout the cylin-
drical diffuser total output power [mW], and Ldif length
[cm] of the diffuser corresponding to the Barretts epithe-
lium length [14]. In this approach, the cylindrical diffuser
is assumed to behave as a radially emitting line source
with the output homogeneously distributed over the cylin-
der surface. Prior to BE PDT the total output power of the
cylindrical diffuser measured in an integrating sphere
(Grasbery Optronics S370, Zevenaar, TeLintelo systems,
The Netherlands) and was set to a value yielding a calcu-
lated fluence rate of 100 mW cm2 for the 3 and 5 cm
cylindrical diffusers, respectively, i.e., 3.9 W for a 5 cm
diffuser in a 2.5 cm balloon diameter.
The fluence rate at the surface of the applicator was
measured using a fiber (400 mm core diameter) with an out
site diameter of 1 mm pseudo sphere isotropic detector at
the distal end (Cardiofocus formerly known as Rare Earth
Medical, West Yarmouth MA), thus measuring the sum of
the primary incident light from the cylindrical diffuser and
the tissue remitted and reflected light. The response of
the detectors was isotropic within 5%. A detailed descrip-
tion on isotropic detectors is given by van Staveren et al.
[15]. The isotropic probes were connected to an electronic
device that enables real time fluence (rate) measurements.
The electronic device was connected to a PC for storage and
processing of the measured data. Calibration of the de-
tectors was performed in a built-in integrating sphere that
provides a well-defined diffuse calibration field. The
dosimetry software applied a factor to correct for the dif-
ference in response of the detectors when measurements
are performed at the air/tissue surface resulting from mis-
match in refractive index [16]. Light delivery was per-
formed using an inflatable transparent windowed balloon
(Wizzard X-cell, Wilson-Cook Medical, Inc., Winston-
Salem, NC) The interior of the black non-transparent
capped portions on both sides is coated with a silver-grey
reflective material [17]. Prior to PDT, two probes were
taped (transparent Scotch Magic tape, 3M) to the middle of
the balloon opposite to each other. During PDT, the two
isotropic detectors recorded the fluence rate (f1,2) every
second at two position at the BE surface. Balloon diameter
was 2.5 cm with a transparent window length of either 3 or
5 cm. A KTP/532-dye laser module at 630 nm (Laserscope,
San Jose, CA) was used for light delivery. A cylindrical
diffuser (400 mm fibre core diameter) (CeramOptec, GmbH,
Bonn, Germany) was aligned in the balloon prior to the
procedure. The length of the balloon and cylindrical dif-
fuser was chosen to be either 3 or 5 cm, corresponding to the
estimated length of the Barrett’s epithelium. This resulted
in two different illumination geometries. Prior to PDT, a
white light endoscopic surveillance was performed and the
guide-wire was positioned. The deflated balloon was posi-
tioned over the guide-wire and then inflated to a pressure of
approximately 60-mm Hg and its position endoscopically
checked. After the guide-wire was removed the cylindrical
diffuser was inserted. The output power of the cylindrical
diffuser was checked prior and post PDT.
Data Processing
The fluence rate was measured every second at two
locations at the BE surface f1(t), f2(t).
Fig. 1. Light applicator with incorporated dosimetry for PDT
of the Barrett’s esophagus (BE) consisting of an inflated win-
dowed transparent balloon with (a) two counter-opposite
isotropic detectors tape in the middle, and (b) a channel for
the cylindrical diffuser. (Color figure can be viewed in the on-
line issue, which is available at www.interscience.wiley.com)
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The mean of the actual measured fluence rate per illu-
mination session was calculated according to Equation 2.
factual ¼
1
T
ZT
0
f1ðtÞþf2ðtÞ
2
dt ð2Þ
where T stands for the total illumination time in seconds.
For each patient the fluence rate amplification factor F is
determined which is the ratio of the actual fluence rate
factual and the first order approximation of the primary
fluence rate in absence of tissue according to Equation 3
[13].
Fi; j ¼ factualfprimary
ð3Þ
For each patient (i) the fluence rate amplification factor
for first and second illumination ( j) were calculated. To
investigate possible acute tissue response as result of the
first illumination we have determined if there was a
significant difference between Fi,1 and Fi,2 could be
observed.
PATIENTS
In this prospective study, 15 patients with BE with
estimated lengths varying from 2 to 5 cm, with low and
high-grade dysplasia were randomly subdivided in various
illumination schemes. After oral administration of 60 mg/
kg ALA (Sigma-Aldrich Chemie BV. Zwijdrecht, Nether-
lands). PDT illumination schemes were: single illumina-
tion of 100 J cm2 4 hours after ALA administration, or
fractionated: either two times 100 J cm2 (4 and 5 hours
after ALA administration) or 20–100 J cm2 (1 and 4 hours
after ALA administration). The patients were sedated
with an intravenously injection of 5–10 mg midazolam
(Dormicum1, Roche Nederland B.V., Mijndrecht, The
Netherlands).
RESULTS
In Figures 2 and 3 examples of in situ fluence rate
measurements during PDT are shown. Figure 2 illustrates
the fluence rate versus treatment time of a patient receiv-
ing a two-fold illumination with a intended primary fluence
of 20 and 100 J cm2, and fprimary 100 mW cm
2 at 630 nm.
The average fluence rates during the first illumination
period were f1¼ 152  7 mW cm2 and f2¼ 162  5 mW
cm2 and showed relatively small variations for the two
detector positions 1 and 2, respectively. The average flu-
ence rate delivered to the tissue during the second illumina-
tion period was f1¼ 168  22 mW cm2 and f2¼ 173  25
mW cm2 for the two detector positions, respectively. The
fluence rate amplification factors as calculated with Equa-
tion 3 were Fi,1¼ 1.6 and Fi,2¼ 1.7 for the first and second
illumination period, respectively.
Figure 3 shows the fluence rate versus treatment time of
a patient receiving a two-fold illumination with a intended
primary fluence of two times 100 J cm2,fprimary¼ 100 mW
cm2 at 630 nm. Large variations in fluence rate were
measured. During the first illumination period, the dif-
ference in actual fluence rate between both locations was
a factor 1.6. The fluence rate amplification factors Fi,1 and
Fi,2 were 3.3 and 2.7 for the first and second illumination
period.
Coughing, and spasm of the esophagus corresponded
with large variations in fluence rate as recorded during
PDT, smaller variations of the signal are possibly due to
motion artefacts from respiration and heartbeat. The
largest variation coincided with patient movement. Smal-
ler variations were recorded when the patient was calm
after additional administration of midazolam.
Fig. 2. Fluence rate [mW cm2] measured in time [second]
during a two-fold PDT illumination 630 nm of the BE at two
opposite positions (f1, f2 at 1 sample per second). The fluence
rates amplification factors were 1.6 and 1.7 during the first and
second illumination respectively (according to Eq. 3). The de-
sired calculated fluence was 20 and 100 J cm2 using a fluence
rate of 100 mW cm2 (Eq. 1). Diffuser lengthLdif¼ 3 cm and the
balloon diameter Dball¼ 2.5 cm.
Fig. 3. Fluence rate [mW cm2] measured in time [second]
during a two-fold PDT illumination 630 nm of the BE at
two opposite positions (f1, f2 at 1 sample per second). The
fluence rate amplication factors (Eq. 3) were on average 3.3
and 2.7 during the first and second illumination respectively.
The desired calculated fluence was 2 100 J cm2 using a
fluence rate of 100 mW cm2 (Eq. 1). Diffuser lengthLdif¼ 5 cm
and the balloon diameter Dball¼ 2.5 cm.
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In eight patients, the fluence rate amplification factor
F was determined twice during a two-fold illumination. If
the treatment would influence the optical properties of
the tissue enough, then the second F would always differ
in the same manner for all patients. A paired t-test was used
to test the hypothesis Fi,1¼Fi,2, the t value was found to be
0.13321 at 12 degrees of freedom, i.e., that at any
reasonable significance level there is no significant differ-
ence between Fi,1, Fi,2 during the first and the second
illumination in a single patient.
Figure 4 summarises the fluence rate amplification Fi,1
and Fi,2 factors during PDT for all patients as a function of
illumination geometries, i.e., ratio of diffuser length and
balloon diameter (Ldif/Dball). A Students t-test revealed
significant difference (P< 0.005) between both geometries.
The average fluence rate amplification factors F for both
geometries were 1.8 (SD 0.5) and 2.8 (SD 0.5), respectively.
CONCLUSION
As seen in Figure 3, the fluence rate can either increase
at one measurement position while remaining stable at
the other, or increase or decrease at both positions simul-
taneously. This gives a clue to the nature of these
variations. When the patient coughs or an esophageal
spasm occurs, muscles contract around the balloon. This
squeezes blood out of the tissue, resulting in an increase in
fluence rate build-up factor on both measurement locations
simultaneously. The single sided variations should have a
more local origin. Normal squamous epithelium often has a
whitish colour whereas Barrett’s columnar epithelium is
more reddish-pink. Due to movement of the balloon, the
position of the isotropic detectors at the mucosa surface will
vary slightly. Thus when a detector is positioned in the
vicinity of a clear junction between squamous and Barrett’s
epithelium, local fluence rate variations may also occur.
Although the fluence rate amplification is not a local effect,
but mainly influenced by the optical properties of the whole
esophageal wall, local colour variations will influence the
actual fluence rate measured at that certain location.
The cylindrical diffuser was not fixed in the middle of the
balloon but usually slightly bent, one probe was always
located closer to the diffuser, thus measuring the highest
primary fluence rate at the balloon surface. The large
difference in fluence rate between both positions during the
first illumination as seen in Figure 3, may be attributed to
an eccentric position of the cylindrical diffuser resulting
from the patients spasms. Murrer et al. [18] investigated
the influence of off-axis positioned cylindrical diffuser using
Monte Carlo simulations in a trachea model and showed
that central off-axis deviations may result in serious over-
dosing at the surface closest to the cylindrical diffuser. As
seen in Figure 4, the fluence rate amplification factor de-
pends on the illumination geometry. In case of small dif-
fuser lengths, relative more light is scattering isotropically
into the absorbing part of the balloon (Fig. 1). Due to this,
the contribution of backscattered light to the measured
fluence rate at the tissue surface will be smaller. This may
explain the difference in fluence rate build-up factor be-
tween the two diffuser lengths. Panjehpour et al. [19,20]
also measured the fluence (rate) in a normal canine eso-
phagus model using isotropic detectors. They found rela-
tively small variations of approximately  12% between
the (n¼ 8) different animals. In that study the detectors
were placed on three healthy tissue positions. From their
data we have calculated a fluence rate amplification factor
F¼ 0.64 according to Equation 3. In a similar animal study
by Overholt et al. [21], using a 1808windowed balloon (black
coating over half the balloon window length) the measured
fluence rate was shown to be less than with a 3608 balloon.
From their data we calculated an F of 0.43, which is much
lower than what was measured in the present study. The
explanation for this apparent discrepancy may be due to
the illumination geometry and less backscattering from
the balloon surface. Murrer et al. [18] described the cylin-
drical diffuser as the superposition of a series of isotropic
point sources. This approach predicts a smaller fluence
rate amplification factor for shorter diffusers due to axial
loss of light. In addition, the effect of multiple reflections
on the fluence rate amplification factor, not included in
this analysis, will increase the losses for shorter dif-
fuser lengths.
Van den Bergh et al. [22] highlighted the importance of
standardising illumination devices and treatment proce-
dures. They concluded that the comparison of the results
between centres performing PDT in the esophagus would
be much improved if procedures and light delivery devices
we optimised and that this may also lead to improved
treatment outcomes. Treatment outcome is also influenced
by photosensitiser selectivity. Insufficient selectivity may
Fig. 4. The fluence rate amplification factorFi,j (measured, i.e.,
scattered plus nonscattered fluence rate, divided by the
calculated fluence rate) as a functions of the illumination
geometries used. Each point represents a patient F during the
first or second illumination.
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result in stenosis or fistulas could be compensated to a cer-
tain extent with accurate light dosimetry as opposed by
Bays et al. [23]. Furthermore, they had measured the
fluence rate distribution as a function of penetration depth
in ex-vivo human esophagus tissue. From their data we
have derived a fluence rate amplification factor at the oesa-
phagus mucosa surface of approximately 2 and 1.7 for 630
and 514 nm, respectively. van den Boogert et al. (1998) [24]
found similar results for in vivo measurement in an animal
study; F¼ 2.4 and F¼ 1.3 for l¼ 633 nm and l¼ 532 nm,
respectively and found less epithelial damage at 523 nm
which was attributed to differences in optical properties,
e.g., strong blood absorption and higher scattering result-
ing in a lower F. PDT of the BE using 514 nm (unpublished
data) resulted in fluence rate amplification factors ranging
from 0.8 to 1.8. The use of small isotropic detectors placed at
the mucosa tissue surface will not result in under dosing
underneath the detector surface as light will be scattered
around the isotropic detector [25].
In this study large variations were seen between the
calculated and measured fluence rate, furthermore differ-
ences by a factor 2 to 3 in fluence rate were measured
between the two opposite detectors, these variations may
seriously alter the clinical response. For photosensi-
tisers such as ALA induced PpIX risk of over-treatment is
not very large, due to photobleaching. Insufficient treat-
ment, however, may increase local recurrences, which has
been observed frequently. With other photosensitisers like
m-THPC [26], or Photofrin [27] over-treatment may result
in excessive PDT damage.
A large variability of the fluence rate was observed
during PDT. Firstly, a major cause of variation was patient
movement, coughing, and esophageal spasm. Secondly,
the fluence rate amplification factor varied in the range
of 1.5–3.9 for 15 patients and appeared to depend on the
redness of the BE. Thirdly, eccentric positioning of the
cylindrical diffuser resulted in significant difference in flu-
ence rate delivered to opposite sites of the BE esophagus.
Finally, the actual fluence rate delivered to the mucosal
surface depended on the illumination geometry. All these
factors appear to justify the routine application of in vivo
dosimetry in PDT of BE especially for potent photosen-
stisers such as HpD or m-THPC. No significant differences
in fluence rate amplification were measured between the
first and second illumination during a two-fold PDT.
REFERENCES
1. Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner
N. Eradication of high-grade dysplasia in columnar-lined
(Barrett’s) esophagus by photodynamic therapy with endo-
genously generated protoporphyrin IX. Lancet 1996;348:
584–585.
2. van den Boogert J, Houtsmuller AB, de Rooij FW, de Bruin
RW, Siersema PD, van Hillegersberg R. Kinetics, localiza-
tion, and mechanism of 5-aminolevulinic acid-induced por-
phyrin accumulation in normal and Barrett’s-like rat
esophagus. Lasers Surg Med 1999;24:3–13.
3. Ackroyd R, Brown N, Vernon D, Roberts D, Stephenson T,
Marcus S, Stoddard C, Reed M. 5-Aminolevulinic acid photo-
sensitization of dysplastic Barrett’s esophagus: A pharmaco-
kinetic study. Photochem Photobiol 1999;70:656–662.
4. de Bruijn HS, van der Veen N, Robinson DJ, Star WM.
Improvement of 5-aminolevulinic acid based photodynamic
therapy in vivo using light fractionation with 75 minute
interval. Cancer Res 1999;59:901–904.
5. Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR,
Brown SB, Star WM. Fluorescence photobleaching of ALA-
induced protoporphyrin IX during photodynamic therapy of
normal hairless mouse skin: The effect of light dose and
irradiance and the resulting biological effect. Photochem
Photobiol 1998;67:141–149.
6. Barr H. Barrett’s esophagus: Treatment with 5-aminolevu-
linic acid photodynamic therapy. Gastrointest Endosc Clin N
Am 2000;10:421–437.
7. Gossner L, May A, Sroka R, Stolte M, Hahn EG, Ell C.
Photodynamic destruction of high grade dysplasia and
early carcinoma of the esophagus after the oral adminis-
tration of 5-aminolevulinic acid. Cancer 1999;86:1921–
1928.
8. Tan WC, Fulljames C, Stone N, Dix AJ, Shepherd N, Roberts
DJ, Brown SB, Krasner N, Barr H. Photodynamic therapy
using 5-aminolaevulinic acid for oesophageal adenocar-
cinoma associated with Barrett’s metaplasia. J Photochem
Photobiol B 1999;53:75–80.
9. Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA,
Thorpe SM, Spencer GM, Hatfield AR, Bown SG. Photo-
sensitisation and photodynamic therapy of oesophageal, duo-
denal, and colorectal tumours using 5 aminolaevulinic acid
induced protoporphyrin IX—a pilot study. Gut 1995;36:67–
75.
10. Maier A, Tomaselli F, Gebhard F, Rehak P, Smolle J, Smolle-
Juttner FM. Palliation of advanced esophageal carcinoma by
photodynamic therapy and irradiation. Ann Thorac Surg
2000;69:1006–1009.
11. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL,
Stoddard CJ, Johnson AG, Reed MW. Photodynamic therapy
for dysplastic Barrett’s esophagus: A prospective, double
blind, randomised, placebo controlled trial. Gut 2000;47:612–
619.
12. van Staveren HJ, Keijzer M, Keesmaat T, Jansen H,
Kirkel WJ, Beek JF, Star WM. Integrating sphere effect in
whole-bladder wall photodynamic therapy: III. Fluence mul-
tiplication, optical penetration, and light distribution with an
eccentric source for human bladder optical properties. Phys
Med Biol 1996;41:579–590.
13. Murrer LHP, Marijnissen HPA, Baas P, Star WM. Applicator
for light delivery and in situ light dosimetry during endo-
bronchial photodynamic therapy: First measurements in
humans. Lasers Med Sci 1997;12:253–259.
14. Murrer LHP, Marijnissen HPA, Star WM. Ex vivo light
dosimetry and Monte Carlo simulations for endobronchial
photodynamic therapy. Phys Med Biol 1995;40:1807–
1817.
15. van Staveren HJ, Marijnissen HPA, Aalders MCG, Star WM.
Construction, quality assurance and calibration of spherical
isotropic fibre optic light diffusers. Lasers Med Sci 1995;10:
137–147.
16. Marijnissen HP, Star WM. Calibration of isotropic light
dosimetry probes based on scattering bulbs in clear media.
Phys Med Biol 1996;41:1191–1208.
17. Panjehpour M, Overholt BF, Haydek JM. Light sources and
delivery devices for photodynamic therapy in the gastro-
intestinal tract. Gastrointest Endosc Clin N Am 2000;10:
513–532.
18. Murrer LH, Marijnissen HP, Star WM. Monte Carlo simula-
tions for endobronchial photodynamic therapy: The influence
of variations in optical and geometrical properties and of
realistic and eccentric light sources. Lasers Surg Med 1998;
22:193–206.
19. Panjehpour M, Overholt BF, DeNovo RC, Sneed RE, Petersen
MG. Centering balloon to improve esophageal photodynamic
therapy. Lasers Surg Med 1992;12:631–638.
20. Panjehpour M, Overholt BF, DeNovo RC, Petersen MG,
Sneed RE. Comparative study between pulsed and continuous
wave lasers for Photofrin photodynamic therapy. Lasers Surg
Med 1993;13:296–304.
IN SITU LIGHT DOSIMETRY DURING PDT FOR BARRETT’S 303
21. Overholt BF, Panjehpour M, DeNovo RC, Petersen MG.
Photodynamic therapy for esophageal cancer using a 180
degrees windowed esophageal balloon. Lasers Surg Med
1994;14:27–33.
22. van den Bergh H. On the evolution of some endoscopic light
delivery systems for photodynamic therapy. Endoscopy
1998;30:392–407.
23. Bays R, Wagnieres GA, Robert D, Braichotte DR, Savary J-F,
Monnier P, van den Bergh H. Light dosimetry for photo-
dynamic therapy in the esophagus. Lasers Surg Med 1997;20:
290–303.
24. van den Boogert J, van Staveren HJ, de Bruin RW, Eikelaar
JH, Siersema PD, van Hillegersberg R. Photodynamic
therapy for esophageal lesions: Selectivity depends on wave-
length, power, and light dose. Ann Thorac Surg 1999;68:
1763–1769.
25. Jode de ML. Monte Carlo simulations of the use of isotropic
light dosimetry probes to monitor energy fluence in biological
tissue. Phys Med Biol 1999;44:3027–3037.
26. Gossner L, May A, Sroka R, Ell C. A new long-range
through-the-scope balloon applicator for photodynamic ther-
apy in the esophagus and cardia. Endoscopy 1999;31:370–
376.
27. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results
of photodynamic therapy for ablation of dysplasia and early
cancer in Barrett’s esophagus and effect of oral steroids
on stricture formation. Am J Gastroenterol 2000;95:2177–
2184.
304 VAN VEEN ET AL.
